Respiratory failure & ventilation

Effect of a driving pressure-limiting strategy for patients with acute respiratory distress syndrome secondary to community-acquired pneumonia: the STAMINA randomised clinical trial

Br J AnaesthPublished Randomised controlled trial

Primary resultResult — go to the resultProportional OR 0.72 95% CI 0.39–1.32
  • stopped early for recruitment fatigue
  • Trial stopped because of recruitment fatigue after 214 patients were randomised

Authors' conclusion

In patients with moderate to severe ARDS secondary to community-acquired pneumonia, a driving pressure-limiting strategy did not increase the number of ventilator-free days compared with a standard low PEEP strategy within 28 days.

Study context

Population
Adults with moderate to severe acute respiratory distress syndrome (ARDS) secondary to community-acquired pneumonia198 analysed
Participants
214 adults
Comparison
Driving pressure-limiting strategy vs low positive end-expiratory pressure (PEEP) strategy
  • Driving pressure-limiting strategyn = 96
  • Low PEEP strategyn = 102reference
Primary endpoint
Ventilator-free days
Follow-up
28 days
Methodological detailsmulticentre
  • Multicentre

Primary result

As reported in the abstract

Proportional OR

0.72

95% CI 0.39–1.32

P = 0.28

By group

Driving pressure-limiting strategy vs Low PEEP strategy
proportional OR 0.72 (95% CI 0.39–1.32); P = 0.28

Secondary outcomes

Driving pressure up to day 3

Mean difference in driving pressure, intervention vs control
−0.7 cm H2O (95% CI −1.4 to −0.1 cm H2O)

In-hospital and ICU mortality · 90 days

No significant differences regarding secondary outcomes

Original publication

Effect of a driving pressure-limiting strategy for patients with acute respiratory distress syndrome secondary to community-acquired pneumonia: the STAMINA randomised clinical trial. Br J Anaesth. Published 26 November 2024. doi:10.1016/j.bja.2024.10.012

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.